Incubated by Vision Institute, the retinal disease gene therapy developer has secured $52.8m in a round co-led by UPMC Enterprises.

UPMC Enterprises, the commercialisation and venture capital arm of University of Pittsburgh Medical Center, co-led a €44.5m ($52.8m) funding round for France-based ocular therapy developer SparingVision on Wednesday. The round was co-led by investment firm 4Bio Capital and included Bpifrance, Foundation Fighting Blindness, Jeito Capital and Ysios Capital. Incubated by research centre Vision Institute’s incubator,…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.